Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease

Clinics in Liver Disease

Volumn 20, Issue 2, 2016, Pages 339-350

  Hannah, William N ^a   Harrison, Stephen A ^a  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

Bariatric surgery; Diet; Exercise; Nonalcoholic fatty liver disease; Weight loss

Indexed keywords

DOCOSAHEXAENOIC ACID; FRUCTOSE; ICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY ACID; CARBOHYDRATE DIET; EDIBLE OIL;

BARIATRIC SURGERY; BILE DUCT BYPASS; CLINICAL EFFECTIVENESS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ENERGY EXPENDITURE; EXERCISE; EXERCISE INTENSITY; GASTRIC BANDING; HUMAN; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW CARBOHYDRATE DIET; LOW FAT DIET; MORTALITY RATE; NONALCOHOLIC FATTY LIVER; REVIEW; RISK BENEFIT ANALYSIS; STOMACH BYPASS; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; ADMINISTRATION AND DOSAGE; CARBOHYDRATE DIET; DIET; LIFESTYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

BARIATRIC SURGERY; DIET; DIETARY CARBOHYDRATES; DIETARY FATS, UNSATURATED; EXERCISE; FRUCTOSE; HUMANS; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; WEIGHT LOSS;

EID: 84958078771     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2015.10.008     Document Type: Review

References (62)

1. Barrera F., George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis 2014, 18(1):91-112.
2. Ng M., Fleming T., Robinson M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384(9945):766-781.
3. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140(1):124-131.
4. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362.
5. Harrison S.A., Fecht W., Brunt E.M., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009, 49(1):80-86.
6. Huang M.A., Greenson J.K., Chao C., et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005, 100(5):1072-1081.
7. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51(1):121-129.
8. Tendler D., Lin S., Yancy W.S., et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007, 52(2):589-593.
9. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27(1):103-107.
10. Musso G., Cassader M., Rosina F., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55(4):885-904.
11. Patel N.S., Doycheva I., Peterson M.R., et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015, 13(3):561-568.e1.
12. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., et al. Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015, 149(2):367-378.e5.
13. Wong V.W., Chan R.S., Wong G.L., et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2013, 59(3):536-542.
14. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142(7):1592-1609.
15. Rosenzweig J.L., Ferrannini E., Grundy S.M., et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93(10):3671-3689.
16. Jensen M.D., Ryan D.H., Apovian C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. Circulation 2014, 129(25 Suppl 2):S102-S138.
17. Drenick E.J., Simmons F., Murphy J.F. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970, 282(15):829-834.
18. Haufe S., Engeli S., Kast P., et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011, 53(5):1504-1514.
19. de Luis D.A., Aller R., Izaola O., et al. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp 2010, 25(5):730-735.
20. Tappy L., Le K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010, 90(1):23-46.
21. Vos M.B., Kimmons J.E., Gillespie C., et al. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med 2008, 10(7):160.
22. Basaranoglu M., Basaranoglu G., Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr 2015, 4(2):109-116.
23. Abdelmalek M.F., Suzuki A., Guy C., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51(6):1961-1971.
24. Jin R., Welsh J.A., Le N.A., et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients 2014, 6(8):3187-3201.
25. Kanerva N., Sandboge S., Kaartinen N.E., et al. Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr 2014, 100(4):1133-1138.
26. Chung M., Ma J., Patel K., et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 2014, 100(3):833-849.
27. Araya J., Rodrigo R., Videla L.A., et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004, 106(6):635-643.
28. Clarke S.D. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol 2001, 281(4):G865-G869.
29. Calder P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006, 83(6 Suppl):1505S-1519S.
30. Spadaro L., Magliocco O., Spampinato D., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008, 40(3):194-199.
31. Zhu F.S., Liu S., Chen X.M., et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008, 14(41):6395-6400.
32. Cussons A.J., Watts G.F., Mori T.A., et al. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009, 94(10):3842-3848.
33. Parker H.M., Johnson N.A., Burdon C.A., et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012, 56(4):944-951.
34. Argo C.K., Patrie J.T., Lackner C., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 2015, 62(1):190-197.
35. Dasarathy S., Dasarathy J., Khiyami A., et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015, 49(2):137-144.
36. Nogueira M.A., Oliveira C.P., Ferreira Alves V.A., et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2015, [Epub ahead of print].
37. Kang H., Greenson J.K., Omo J.T., et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006, 101(10):2247-2253.
38. McGavock J.M., Anderson T.J., Lewanczuk R.Z. Sedentary lifestyle and antecedents of cardiovascular disease in young adults. Am J Hypertens 2006, 19(7):701-707.
39. Zhu S., St-Onge M.P., Heshka S., et al. Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism 2004, 53(11):1503-1511.
40. Church T.S., Kuk J.L., Ross R., et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 2006, 130(7):2023-2030.
41. Johnson N.A., Sachinwalla T., Walton D.W., et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009, 50(4):1105-1112.
42. St George A., Bauman A., Johnston A., et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009, 50(1):68-76.
43. Hallsworth K., Fattakhova G., Hollingsworth K.G., et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011, 60(9):1278-1283.
44. Keating S.E., Hackett D.A., George J., et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012, 57(1):157-166.
45. Eckard C., Cole R., Lockwood J., et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol 2013, 6(4):249-259.
46. Gerber L.H., Weinstein A., Pawloski L. Role of exercise in optimizing the functional status of patients with nonalcoholic fatty liver disease. Clin Liver Dis 2014, 18(1):113-127.
47. Wu T., Gao X., Chen M., et al. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obes Rev 2009, 10(3):313-323.
48. Thoma C., Day C.P., Trenell M.I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. Journal of Hepatology 2012, 56(1):255-266.
49. Vilar Gomez E., Rodriguez De Miranda A., Gra Oramas B., et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009, 30(10):999-1009.
50. Buchwald H., Oien D.M. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013, 23(4):427-436.
51. Castagneto-Gissey L., Mingrone G. Insulin sensitivity and secretion modifications after bariatric surgery. J Endocrinol Invest 2012, 35(7):692-698.
52. Mingrone G., Panunzi S., De Gaetano A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012, 366(17):1577-1585.
53. Schauer P.R., Kashyap S.R., Wolski K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012, 366(17):1567-1576.
54. Ikramuddin S., Korner J., Lee W.J., et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013, 309(21):2240-2249.
55. Pontiroli A.E., Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg 2011, 253(3):484-487.
56. Adams T.D., Gress R.E., Smith S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007, 357(8):753-761.
57. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121(1):91-100.
58. Bower G., Toma T., Harling L., et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg 2015, [Epub ahead of print].
59. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
60. Mathurin P., Hollebecque A., Arnalsteen L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009, 137(2):532-540.
61. Alizai P.H., Wendl J., Roeth A.A., et al. Functional liver recovery after bariatric surgery-a prospective cohort study with the LiMAx test. Obes Surg 2015, 25(11):2047-2053.
62. Stockmann M., Lock J.F., Riecke B., et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009, 250(1):119-125.